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Objective: To determine specific antibody levels against Helicobacterpyloriantigens in stool and saliva specimens from 
H. pylori-infected subjects and seronegative controls. 
Methods: Antibody levels against a total membrane preparation (MP) and purified flagellin from H. pylori  were 
measured by enzyme-linked immunosorbent assays (ELISAs) in  fecal extracts (FEs) and sera from 21 H. pylori-infected 
and 17 non-infected adult Swedish volunteers; specific antibody levels in saliva (IgG and IgA titers) were also measured 
in the majority of them. Follow-up specimens after successful eradication of H. pyloriwere collected after 5-7 weeks (all 
specimens) and 5 months (FEs and sera). 
Results: Geometric mean specific IgA antibody levels, adjusted to total IgA concentration, in  FEs were significantly 
higher (p<0.05) in the H. pylori-infected than in the control group against MPs (p<0.05) and flagellin (~‘0.05). The total 
IgA concentrations in  FEs from infected and seronegative controls were comparable and the IgA was mainly of the 
secretory type. Saliva specimens from H. pylori-infected subjects had higher ELISA IgA than IgG titers against MP. Anti- 
MP antibodies of both isotypes were higher in the infected than in the non-infected group (p<0.05 for both isotypes). 
The total IgA levels were also significantly (~‘0.05) higher in saliva from the H. pylori-infected subjects than in saliva 
from the controls (geometric mean 292 mg/L and 173 mg/L, respectively). Eradication therapy resulted in  a more rapid 
decline in antibody levels in  FEs than in corresponding sera or saliva specimens. 
Conclusions: Specific antibodies against H. pylori  MP were detected in FEs as well as in saliva from most of the infected 
volunteers, the mean antibody levels being significantly higher in  specimens from the H. pylori-infected subjects than 
from seronegative controls. The results suggest that analyses of antibody levels in FEs may be used for follow-up of 
patients early (5-7 weeks) after onset of successful eradication therapy. 
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INTRODUCTION 
The strong association of Helicobacter pylori infection 
with peptic ulcer disease and gastric cancer has led to a 
search for non-invasive methods for diagnosis of 
infection [l]. Attempts have been made to use 
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specimens that are easily obtained, e.g. dental plaques, 
saliva or feces, for detection of Helicobacter pylori either 
by culture or by polymerase chain reaction (PCK) 
methods [2-91. However, these techniques have been 
found to be time-consuming or to have rather low 
sensitivities; for instance, the presence of inhibitors of 
the amplification reaction in feces may limit the 
usefulness of PCR on stool samples [9 ] .  At present, the 
most widely used non-invasive diagnostic tests are 
serology and the urea breath rests (UBTs) [10,11]. 
Determination of serum antibody levels against 
Helicobacter pylori is a reliable and relatively inexpensive 
technique frequently used as a screening method for 
Helicobacter pylori infection [I 0,121. However, systemic 
antibodies do not necetsarily reflect active infection or 
the immune responses locally in the gastrointestinal 
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tract [13]. Salivary IgG can also be measured with a 
relatively high sensitivity but such antibodies probably 
reflect systemic rather than mucosal B-cell responses 
[14,15]. Instead, the local immune response in the 
stomach mucosa of Helicobacter pylori-infected subjects 
may be determined by assessing antibody-producing 
cells in gastric biopsies or locally produced antibodies, 
predominantly of the IgA isotype, in gastric juice 
[16-181. To date, it has not been investigated whether 
or not Helicobacter pylori-specific antibodies can resist 
intestinal transit and be detected in feces. 
Because of the slow decline of serum antibody 
levels after eradication of Helicobacter pylori, serology 
does not allow any conclusions to be drawn about 
changes in infection status earlier than 3-6 months 
post-therapy [I 9-21]. The UBTs reliably determine 
the outcome of antimicrobial treatment at an earlier 
stage, but they require access to special equipment, and 
if [I4C]urea is used, the method is associated with low 
radiation exposure [11,22]. 
The general objectives of this study were two-fold. 
First, we evaluated the possibility of determining 
specific antibodies against Helicobacter pylori in fecal 
extracts (FEs) and saliva specimens. Second, we invest- 
igated whether specific antibody levels in FEs or sahva 
specimens may decrease more rapidly than serum 
antibody titers after termination of successful eradica- 
tion therapy, which would offer a diagnostic benefit 
when monitoring the response to treatment. 
MATERIALS AND METHODS 
Clinical specimens 
Specimens were obtained from 21 Helicobacter pylori- 
infected Swedish adults (mean age 50 years, range 
22-80 years, nine men) who participated in a parallel 
study at the Department of Surgery, Sahlgrenska 
University Hospital, Goteborg. These subjects were 
diagnosed as being Helicobacterpylori positive by a highly 
accurate capsule-based 14C-UBT before entering the 
study [22]. In a previous study, a 99% concordance 
between the UBT and the serology method used had 
been shown [22]; in subsequent studies, all patients 
with positive Helicobacterpylori culture have been shown 
to have positive serology with the ELISA method used 
[23]. Eight of the subjects had chronic relapsing 
duodenal ulcer (DU) disease (confirmed by endo- 
scopy), five had non-ulcer dyspepsia and eight were 
asymptomatic, with no history of gastrointestinal disease 
or any other relevant illness. The D U  patients were, at 
the time of the investigation, in clinical remission, and 
none of the dyspeptic patients had been treated with 
antisecretory medication for at least 1 week before the 
start of the study. After initial investigation, the Helico- 
bacter pylori-infected subjects were given eradication 
therapy consisting of 40 mg omeprazole and 1.5 g 
amoxycillin twice a day and 400 mg metronidazole 
three times a day for 2 weeks. Successful eradication 
was defined as a negative UBT at the follow-up 6 2 1  
weeks after onset of therapy. Pre- and post-treatment 
sera, salivas and stool specimens were collected on the 
first day of therapy as well as at the time of the follow- 
up UBT at 6 2 1  weeks after the start of antimicrobial 
therapy; additional stool and serum specimens were 
also collected from some of the volunteers 5 months 
after the start of successful eradication therapy. In 
addition, sera, saliva and stool specimens from 17 
Helicobacter pylori-seronegative controls of similar age 
(mean age 37 years, range 24-55 years, eight men) were 
analyzed. 
Sera 
Venous blood was collected and sera obtained after 
centrifugation were stored at -2OOC until analyzed. 
Stool specimens 
Stool samples, 15-20 g, were collected in plastic cups 
and kept at 4OC for up to 8 h before being frozen at 
-70°C. Within 1 month after collection, the frozen 
specimens were thawed and further processed by 
dilution 1 :5 (w/v) in phosphate-buffered saline (PBS, 
pH 7.2), containing 0.05% Tween-20, 0.1 m g / d  
soybean trypsin inhibitor (STI, Sigma Chemical Co., 
St Louis, Mo, USA), 0.05 M EDTA (Merck, 
Darmstadt, Germany) and 0.35 mg/mL phenylmethyl- 
sulfonyl fluoride (PMSF, Sigma Chemical Co., St 
Louis, Mo, USA) [24]. The slurry was homogenized 
for 15 min and then centrifuged at 20 000g for 30 min 
in a high-speed centrifuge (Beckman Instruments, 
Bromma, Sweden). Bovine serum albumin (BSA, 
Sigma Chemical Co., St Louis, Mo, USA) and NaN03 
(BDH Laboratory Supplies, Poole, UK) were added to 
the supernatants at  final concentrations of 1 mg/mL 
and 0.2 mg/mL, respectively. The FEs were frozen in 
aliquots at  -7OOC until analysis. 
Saliva specimens 
At the time of the UBT, a 5-mL saliva sample was 
collected from each subject and immediately put on ice. 
The saliva specimens were centrifuged at 2040g for 
2 min, and BSA, STI and PMSF were added to the 
supernatants at final concentrations of 1 mg/mL, 
0.1 mg/mL and 0.35 mg/mL, respectively, to minimize 
proteolytic degradation. If the specimens were very 
viscous, acetylcysteine (Tika Lakemedel AB, Lund, 
Sweden), at  a final concentration of 10 mg/mL, was 
added before specimens were frozen at -70°C. 
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Bacterial strains and growth conditions 
Helicobacter pylori bacteria of strain C C U G  17874 
(NCTC 11637), obtained from the Culture Collection, 
Goteborg University, and strains E32 and E50, kindly 
provided by J.-P. Butzler, St Pieters Hospital, Brussels, 
were used in the study. The strains were kept at -70°C 
in freeze medium containing 20% v/v glycerol until 
use. Bacteria were cultured on horse blood agar plates 
at 37°C for 72 h under micro-aerophilic conditions, 
with an atmosphere of 10% C02,  5% 0 2  and 85% N2 
and then cultured on new agar plates for 48 h before 
harvesting. 
Bacterial antigens 
Total membrane preparations (MPs) were prepared 
from Helicobacter pylori strains CCUG 17874 and E50, 
according to the modified method of Achtman et al as 
previously described [25,26]. Acid glycine extracts were 
prepared from strain CCUG 17874 [19]. 
Flagellin was purified from Helicobacter pylori strain 
E32, by a modification of the method described by 
Kostrzynska et a1 [27]. Briefly, bacteria were homo- 
genized with an Ultra-Turrax blender (IKA- 
Laborteknik, Staufen, Germany) before centrifugation 
at 20 0008 for 1 h at  4OC in a high-speed centrifuge 
(Beckman Instruments, Bromma, Sweden) for removal 
of deflagellated cells; the bacterium-free supernatant 
was then centrifuged at 100 000g for 1 h. The resulting 
pellets were resuspended in 20 mM Tris-HC1 buffer, 
pH 7.8, containing 20 mM CaC12. After addition of 
trypsin (Sigma Chemical Co., St Louis, Mo, USA) at a 
final concentration of 1 mg/mL, the mixture was incu- 
bated at 37°C for 90 min. The reaction was stopped by 
adding an excess amount of STI (Sigma Chemical Co., 
St Louis, Mo, USA). Further purification was achieved 
by CsCl equilibrium density gradient centrifugation 
(Pharmacia Fine Chemicals, Uppsala, Sweden) in 
1.27 g/cm3 CsCl at  180 000g at room temperature for 
20 h. The band collected from the gradient was 
dialyzed overnight against PBS, prior to application of 
the material to a Resource Q column on FPLC 
(Pharmacia Fine Chemicals, Uppsala, Sweden). Pro- 
teins were eluted with a 0-100% gradient of 500 mM 
NaCl. The eluted peaks were analyzed by Phast gel 
electrophoresis (10-1 5% sodium dodecylsulphate 
(SDS)-polyacrylamide gel electrophoresis (PAGE), 
Pharmacia Fine Chemicals, Uppsala, Sweden) and by 
immunoblotting using a monoclonal antibody (MAb) 
against the Helicobacter pylori flagellin [28]. 
Determination of total IgA and specific antibody titers 
Total IgA contents in FEs and saliva specimens were 
determined by a modified microplate enzyme-linked 
immunosorbent assay (ELISA) method, as previously 
described [ 13,161. A Swedish human milk specimen as 
well as a commercially available colostrum IgA standard 
(Sigma Chemical Co., St Louis, Mo, USA) were used 
as references. Specimens with a total IgA concentration 
120 mg/L were excluded from the study, since previous 
results have shown that FEs with lower total IgA 
concentration do not give reproducible results when 
used for antibody determinations [29]. Specimens from 
a subject were also excluded if the total IgA concen- 
tration in the pre- and post-treatment FE samples 
differed 210-fold [29]. 
Specific IgA and IgG antibody titers in sera and 
saliva specimens against MPs of strain CCUG 17874 
were determined by ELISA. Briefly, plastic microtiter 
plates (Nunc A/S, Roskilde, Denmark) were coated 
with 25 mg protein/L at room temperature overnight. 
The plates were then washed twice in PBS and blocked 
with 0.1% BSA-PBS at 37°C for 30 min. Sera and 
saliva samples, at  initial dilutions of 1:30 and 1:2 
respectively, were diluted three-fold in 0.1% BSA- 
PBS-0.05% Tween. After incubation at room temper- 
ature for 90 min, HRP-conjugated rabbit antihuman 
IgG or IgA (Jackson Immuno Research Laboratories, 
West Grove, Pa, USA) were added as secondary 
antibodies, and incubation was continued for another 
90 min. The absorbance was measured at 450 nm in a 
photometer (Labsystems, MultiscanPLUS, Sweden) 
after incubation with H202 and orthophenylenediamine 
dihydrochloride (OPD, Sigma Chemical Co., St Louis, 
Mo, USA) in 0.1 M sodium citrate buffer, pH 4.5, for 
20 min. The endpoint titers were determined as the 
reciprocal dilution giving an absorbance of 0.4 above 
background [30]. 
For detection of specific IgA antibodies in FEs, 
specimens at an initial dilution of 1:2 were tested for 
titers against MP as described above, or against purified 
flagellin, 5 mg/L in PBS, at room temperature over- 
night. The test was followed as described above, with 
the difference that 25 pL of 1 M H2SOa was added to 
the substrate-containing wells and reading was per- 
formed at 492 nm. Specimens with a specific antibody 
titer <2 in the ELISA (before adjustment for total IgA) 
were arbitrarily assigned a titer of 1. 
Secretory IgA (sIgA) as a proportion of total IgA 
in FEs and saliva specimens was determined in an 
antisecretory component ELISA, run in parallel with 
the total IgA ELISAs, using goat antihuman IgA 
(Jackson Inimuno Research Laboratories, West Grove, 
Pa, USA) for coating and HRP-conjugated goat anti- 
human secretory component (SC) (Nordic Immuno- 
logy, Tilburg, The Netherlands) as secondary antibody. 
A Swedish milk specimen, in which 95% of the total 
IgA was sIgA, and the Sigma colostrum IgA standard 
containing >90% sIgA, were included as references. 
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Four human sera were included as controls and did not 
give any titer when the anti-SC conjugate was used as 
secondary antibody. 
Titers were adjusted in relation to reference 
specimens included in each test to adjust for variations 
of analyses on different occasions. Pre- and post-treat- 
ment specimens from the same volunteer were always 
examined in the same test. The specific IgA antibody 
titers in FEs and saliva specimens were divided by the 
total IgA concentration to adjust for variations in the 
IgA concentration in specimens collected from differ- 
ent individuals and on different days; given values are 
the means of two or three determinations of IgA titers 
and total IgA for each sample analyzed on different 
occasions. 
Statistics 
The Mann-Whitney t-test was used for statistical 
analysis of antibody titers in FEs and saliva specimens. 
Correlation coefficients were calculated with the 
Spearman rank test. Based on calculations of the 
methodological error for different ELISA tests in our 
laboratory, a 21.5-fold difference in titer between 
samples taken on different occasions against a certain 
antigen has been shown to be statistically significant 
( ~ 1 0 . 0 5 )  [30]. In this study, a 22-fold difference in titer 
between pre- and post-treatment specimens was chosen 
to indicate a significant difference. 
RESULTS 
Antibody levels in FEs 
Fecal extracts of stool specimens from 21 Helicobacter 
pylori-infected subjects who were all seropositive and 
UBT positive, and from 17 healthy individuals with 
negative Helicobacter pylori serology, were analyzed for 
total IgA and Helicobacter pylori-specific antibodies in 
the ELISA. The geometric mean total IgA concentra- 
tions in FEs obtained from Helicobacter pylori-positive 
and seronegative subjects were similar; 162 and 
146 mg/L, respectively. When the proportion of IgA- 
containing SC in FEs was determined, it was found that 
70-80% of the total IgA in specimens from infected 
subjects and from controls was sIgA (data not shown). 
Analyses of FEs for antibodies against Helicobacter 
pylori showed specific IgA antibody levels against MP 
as well as flagellin in most of the specimens collected 
from the Helicobacter pylori-infected subjects. The anti- 
MP and anti-flagellin IgA levels (specific IgA titer per 
total IgA) in specimens from the ffelicobacfer pylori- 
I*l 
Helicobacter 
0 Controls 
pylori-in fected 
anti-MP anti-Flagellin 
Figure 1 Geometric mean (kSEM) specific IgA titers adjusted to total IgA concentrations against a Helicobacter pylori 
membrane preparation (MP) and Helicobacter pylori flagellin, respectively, in fecal extracts (FEs) &om Helicobacter pylori-infected 
subjects and seronegative controls. Asterisks denote a statistically significant (p < 0.05) difference between subjects and 
controls. 
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infected subjects were significantly ( p <  0.05) higher 
than in FEs from the seronegative controls (Figure 1). 
Indeed, as many as 19 of the 21 Helicobacter pylori- 
infected subjects had detectable specific IgA titers 
against MP in FEs (before adjustment for total IgA). 
However, specific IgA titers against M P  were also 
detected in FEs from six of the 17 seronegative 
controls. 
For control purposes, we determined IgA anti- 
body levels in FEs against MP from Helicobactev pylori 
strain E50 to compare immune responses against MPs 
from different strains. We also analyzed specimens 
against wells coated with 1% BSA to exclude non- 
specific binding. These analyses showed comparable 
IgA antibody levels against MPs from strains C C U G  
17874 and E50, whereas only one specimen, from a 
seronegative control, showed a detectable IgA titer 
when BSA was used for coating (data not shown). 
Specific antibodies against an acid glycine extract of 
Helicobacter pylori strain CCUG 17874 were found in 
FEs from four Helicobacter pylori-infected patients but 
in barely detectable titers. Three of the Helicobacter 
pyluri-infected subjects had specific IgG titers against 
MP in FEs, although of lower magnitudes than the 
corresponding specific IgA titers (data not shown), 
while none of the controls had detectable IgG titers 
in the stool. 
There was no correlation between the IgA titers 
against MP in serum and the anti-MP IgA levels in FEs 
(rF=0.32; p >0.1) when specimens from Helicobacter 
pyluri-infected subjects were studied. 
Antibodies in saliva specimens 
Saliva specimens obtained from 14 of the Helicobacter 
pylori-infected subjects and from 14 seronegative 
controls were also analyzed for antibody levels against 
MP from strain CCUG 17874 in the ELISA. Both IgG 
and IgA titers in salivas from the infected subjects were 
significantly higher than corresponding titers in speci- 
mens from the seronegative controls (Figure 2). The 
total IgA concentrations in salivas from Helicobacterpylori- 
infected subjects were significantly higher ( p  < 0.05) 
than in saliva specimens from controls (geometric 
means 292 and 173 mg/L, respectively). However, the 
proportion of total IgA that was sIgA was the same, i.e. 
a mean of 80%, in saliva specimens from both 
Helicobacter pylori-infected and seronegative controls 
(data not shown). 
The IgG titers against MP in salivas from the 
infected subjects correlated significantly with corres- 
IgG titer 
r * i  
.801 
.. 
. 
301 
IgA titer 
r * i  * *  
**  
4 
** 
0 
O 0  
4 
Figure 2 Specific IgG and IgA antibody titers against MP in saliva specinlens obtained from HeIicobacter pylori-infected 
(closed symbols) subjects and seronegative (open symbols) controls. Subjects with titers < 2 were arbitrarily assigned a titer of 
1. Asterisks denote a statistically significant 0, < 0.05) titer difference; horizontal lines denote geometric means. 
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ponding IgG titers in sera (rs=0.65; p<O.O2), whereas 
there was no correlation between IgA titers in saliva and 
serum of Helicobacter pylori-infected subjects (rs= 0.27; 
p>O.l). 
Follow-up of antibody levels after eradication of 
Helicobacter pylori 
We also analyzed antibody levels in sera and FEs at 6 
weeks and 5 months after eradication of Helicobacter 
pylori. Successful eradication of Helicobacter pylori was 
achieved in 13 of 17 initially Helicobacter pylori-infected 
subjects available for follow-up after treatment. Since 
FEs from four subjects did not meet the inclusion 
criteria [29], the analysis of antibody levels in follow- 
up specimens included nine subjects. 
As shown in Table 1 and Figure 3, significant 
decreases in specific IgA titedtotal IgA in FEs were 
observed in seven of nine subjects 6 weeks after onset 
of therapy as compared to before treatment. After 5 
months, four of the six subjects from whom late 
specimens were collected showed significantly lower 
specific IgA levels in FEs as compared to in FEs 
collected before onset of treatment (Figure 3). In 
contrast, when specific antibody levels in serum were 
analyzed, two of nine patients showed 22-fold decreases 
in IgA titer and only one showed a significant IgG titer 
decrease after 6 weeks (Table 1). After 5 months, one 
of six patients showed a decrease in IgA titer. However, 
significant decreases in serum IgG antibody levels were 
ob4erved in five of six volunteers (Figure 3) .  
Analyses of repeat specimens, taken 5-6 weeks 
apart from six patients before onset of therapy as well 
as from six of the controls, for specific antibodies and 
total IgA concentrations in FEs showed similar 
antibody levels from the same person, demonstrating 
the reproducibility of the results (data not shown). 
When specific titers in saliva specimens obtained 
before and 6 weeks post-treatment were compared, 
significant decreases in anti-MP IgG and IgA levels 
were only seen in a few cases; the geometric mean 
antibody levels were comparable on both occasions 
(Table 2). 
DISCUSSION 
In the present study, we report the presence of 
Helicobucter pylori-specific IgA antibodies in extracts of 
stool specimens. Detectable levels of IgA against two 
different Helicobacterpylori antigen preparations, MP and 
flagellin, were found in FEs, of most of the Helicobacter 
pylori-infected subjects. The lack of correlation 
between anti-MP IgA titers in sera and FEs and the 
high level of sIgA as a proportion of total IgA in 
the FEs suggest that the specific antibodies were 
indeed locally produced. The absence of detectable FE 
antibodies against MP in two of the 21 Helicobacterpylori- 
infected subjects might be due to degradation of 
antibodies by digestive enzymes or bacterial proteases, 
during either intestinal transit or storage, despite the 
precautions taken; stool samples were stored for up to 
8 h at 4°C and not more than 3 months at  -7OoC, and 
all FEs were treated with enzyme inhibitors. Antibody 
titers against Helicobacter pylori MP were also found in 
FEs of some negative controls, however. We cannot 
exclude the possibility that some of the seronegative 
control subjects with titers in FEs might have been 
infected with Helicobacter pylori at the time of collection 
of the samples, since it has been reported from other 
laboratories, using different serologic methods, that up 
to 5-10% of Helicobacter pylori-infected individuals may 
be seronegative [12,31]. However, the serology method 
used in our study, employing Helicobucter pylori MP as 
antigen, has previously been shown to have 99% 
concordance with the UBT used [22]. The increased 
levels of anti-MP IgA in FEs of seronegative subjects 
may represent falsely positive results. A likely explana- 
Table 1 Decrease in antibody levels against Helicobacter pylovi membrane preparation (MP) in fecal extracts and sera, from 
Helicobacter pylori-infected patients after eradication 
Proportion with decreased levels after eradication 
Sera 
Fecal extracts 
(IgA/total IgA) IgA IgG 
Fold Fold Fold 
After Frequency decreaseb Frequency decrease Frequency decrease 
6 (?I) weeks 7/9 (78%) 2.4 2/9 (22%) 1.4 1/9 (11%) 1.4 
5 months 4/6 (67%) 2.6 1/6 (17%) 1.4 5/6 (83%) 2.9 
'"umber of volunteers showing a significant, i.e. 22-fold. decrease in specific IgA titer/total IgA between pie- and post-treatment samples. 
'Fold decrease in geometric mean specific IgA titedtotal IgA (fecal extracts) or IgA and IgG titer (sera) between pre- and corresponding 
post-treatment specimens. 
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Figure 3 Decreases in specific anti-MP IgG titers in serum and anti-MP IgA titers/total IgA in stool (fecal extracts) 
6 k 1 weeks and 5 months after onset (day 0) of successful eradication therapy. Individual results for the nine different 
volunteers included in the follow-up studies are shown. 
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Table 2 Antibody levels against Helicobacter pylori 
membrane preparation in saliva before and 6?1 weeks after 
onset of eradication therapy 
Anti-MP 
IgA titer/total IgA IgG titer 
Geometric mean Geometric mean 
( k l  SD) ( k l  SD) 
Pretreatment 18.2 (13.5-24.5) 19 (10.5-34.6) 
Post-treatment 16.6 (11.2-24.5) 15.5 (7.2-33.1) 
Proportion with 
significant decrease 0/11, "NS 3/11, NS 
'Two of 11 if IgA titers were not adjusted for total IgA 
NS, no significant decrease in anti-MP levels after as compared to 
before treatment 
tion for this would be the presence of cross-reactive 
antibodies in those extracts. Thus, in previous studies 
antigenic cross-reactivity between Helicobacter pylori, 
Campylobacter jejuni and C. coli flagellins, as well as 
between Helicobacter pylori protein antigens (e.g. the 
heat shock protein GroEL and a 14-kDa antigen) and 
the non-gastrointestinal bacteria Pseudomonas aeruginosa 
and Haemophilus influenzae, have been shown [32,33]. 
Antigen preparations with a complex mixture of 
different proteins favor non-specific reactions or cross- 
reactivity. As previously shown [34], the mean titer 
values in sera against Helicobacter pylori increase with the 
molecular weight of the antigens. The commonly used 
acid glycine extract contains relatively few high- 
molecular-weight antigens, and non-infected subjects 
had low reactivities with this antigen compared with 
reactivities with, for example, MP [34]. In agreement 
with these findings, we have previously observed lower 
titers in sera from Helicobacter pylori-infected and non- 
infected individuals against Helicobacter pylori acid 
glycine extracts than against the corresponding MP 
preparations. However, when FEs from Helicobacter 
pylori-infected subjects were analyzed for specific IgA 
titers against the acid glycine extract in the present 
study, titers were low if detectable at all. When a 
purified Helicobacter pylori antigen was used, i.e. the 
flagellin, specific titers were found in most of the 
infected patients but also in some of the controls. 
However, the control persons with increased flagellin 
levels were not the same ones as those with increased 
MP titers, suggesting that the reactivity in the controls 
indeed represented cross-reactive antibodies against 
flagellin and did not reflect Helicobacter pylori infection. 
The detection of specific salivary IgG antibodies 
from most of the Helicobacter pylori-infected subjects is 
in agreement with other studies [14]. Since there is no 
known system for directed migration of IgG-secreting 
cells to the salivary glands, IgG is thought to be derived 
by transudation from blood to gingival fluid [15,35]. 
The positive correlation between salivary and serum 
IgG values in Helicobacter pylori subjects in this and 
previous studies supports the idea that salivary IgG 
antibodies are serum-derived, i.e. they are probably not 
of mucosal origin. The lack of correlation between IgA 
titers in saliva and serum of Helicobacter pylori-infected 
subjects and the high level of sIgA as a proportion of 
total IgA in saliva, on the other hand, suggest that 
the salivary IgA antibodies were predominantly of 
mucosal origin. Interestingly, the Helicobacter pylori- 
infected subjects had a higher mean total IgA concen- 
tration in saliva than controls. A possible explanation 
for this might be reflux of IgA from the stomach, since 
we have recently shown that gastric mucosa from 
Helicobacter pylori-infected subjects contain =80-fold 
higher numbers of IgA-producing cells than corres- 
ponding biopsies from non-infected subjects [23]. 
Previous studies evaluating the effect of eradication 
therapy have shown the usefulness of measuring a 
decrease of serum IgG antibody titers between pre- and 
post-treatment sera, but subjects must be followed for 
at least 3-6 months to determine the outcome of 
treatment [19-211. Oral and stool samples might have 
advantages over serum samples in ease of collection, 
and recently developed tests for salivary IgG antibodies 
have shown a performance only slightly inferior to that 
of serum IgG [14]. However, it is not known whether 
antibody levels in stool or saliva specimens decrease 
more rapidly than serum antibodies after treatment of 
Helicobacter pylori. In the present study these specimens 
were collected from Helicobacter pylori-infected indi- 
viduals before as well as 6 weeks and 5 months after the 
start of successful eradication therapy. In the majority 
of cases, eradication was reflected by a significant 
decrease of specific IgA antibody levels in FEs already 
after 6 weeks. In contrast, only one subject showed a 
significant IgG titer decrease in serum at this time, and 
none had significant decreases in specific IgA in saliva. 
After 5 months, however, the frequency of subjects 
with significant decreases in specific IgA in FEs was 
comparable to the frequency of subjects showing sig- 
nificant IgG titer decreases in sera. In agreement with 
other studies, we found that determinations of IgG 
titers in serum were more useful for follow-up of 
eradication than serum IgA titers [19-211. Our results 
also clearly show that the IgA antibody levels in FEs 
decline more rapidly after eradication than the 
corresponding levels in saliva and serum. The reason for 
the discrepancy between stool and saliva specimens 
could be the persistence of bacteria in the oral cavity 
after therapy. This explanation is supported by data 
6 4 2  C l i n i c a l  M i c r o b i o l o g y  a n d  
from a recent study using P C R  on saliva and dental 
plaques showing that bacteria persisted in the oral 
cavity for 4 weeks after treatment in subjects with 
negative breath test results [36]. 
In summary, the present study demonstrates that 
IgA antibodies against Helicobactevpylori antigens can be 
detected in FEs of most Helicobactev pylovi-infected 
subjects. However, determination of fecal antibodies 
against Helicobactev pylovi is not a suitable test for 
screening purposes because of its low specificity. Still, 
since eradication treatment was reflected by an earlier 
decline of specific IgA levels in FEs than in serum or 
saliva, measurement of IgA antibody levels in FEs may 
be of some value in monitoring the response to 
eradication therapies. Although UBT is the actual 
reference method for non-invasive follow-up of 
eradication therapy, this method has several limitations, 
such as high costs and the requirement for special 
equipment for I3C or “C determination. Follow-up by 
determination of specific antibody levels in FEs, on the 
other hand, is hampered by the risk of collecting 
specimens that do not fulfill the ‘inclusion criteria’, at 
least the ones established by us [29]. Against this 
background follow-up of eradication treatment by 
determining anti-Helicobacter pylovi antibodies in FEs 
may be considered, e.g. in relatively large population 
studies in locations or populations with poor econoniies 
or when determination of l3C or cannot be accon- 
plished. 
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